21
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2016
Study Completion Date
September 30, 2017
Multivirus-specific T cells Dose Level 1
"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
Multivirus-specific T cells Dose Level 2
"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
Multivirus-specific T cells Dose Level 3
"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston
Lead Sponsor
Baylor College of Medicine
OTHER
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
AlloVir
INDUSTRY